Skip to Content
You are currently on the new version of our website. Access the old version .
MicroorganismsMicroorganisms
  • Comment
  • Open Access

24 September 2019

4 Pages

Lefamulin. Comment on: “Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270”

,
,
,
,
,
,
and
1
UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia
2
2nd Critical Care Department, Attikon University Hospital, 12462 Athens, Greece
3
4th Department of Internal Medicine, Attikon University Hospital, 12462 Athens, Greece
4
Department of Intensive Care Medicine, Royal Brisbane and Women’s Hospital, Brisbane 4029, Australia
This article belongs to the Special Issue Multidrug-Resistant Pathogens

Abstract

On 18 August 2019, an article was published in Microorganisms presenting novel, approved anti-Gram-positive antibiotics. On 19 August 2019, the U.S. Food and Drug Administration announced the approval of lefamulin, a representative of a new class of antibiotics, the pleuromutilins, for the treatment of adult community-acquired bacterial pneumonia. We present a brief description of lefamulin.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.